This Investment Research Paper addresses the issue of renewable power generation in the UK and in mainland Europe, which – after the deep-seated financial crisis of 2008/09 and the ensuing recession – now has better prospects of achieving critical mass. It also considers investment perspectives.
05 Feb 2019
THE MONTHLY February 2019
Time Finance plc (TIME:LON), 37.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 300 | Allergy Therapeutics plc (AGY:LON), 2.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 50.2 | Amala Foods Plc (DISH:LON), 0 | Burford Capital Limited (BUR:LON), 1,143 | City of London Investment Group PLC (CLIG:LON), 326 | DP Poland PLC (DPP:LON), 11.5 | Gateley (Holdings) Plc (GTLY:LON), 123 | Genedrive Plc (GDR:LON), 3.4 | Haydale Graphene Industries Plc (HAYD:LON), 0.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 191 | Palace Capital plc (PCA:LON), 226 | R.E.A. Holdings plc (RE:LON), 70.0 | Redx Pharma Plc (REDX:LON), 21.5 | Shield Therapeutics Plc (STX:LON), 2.1 | Surface Transforms PLC (SCE:LON), 9.6 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.5 | Titon Holdings Plc (TON:LON), 80.0 | Volta Finance Limited (VTA:LON), 512 | Warpaint London PLC (W7L:LON), 420 | ValiRx PLC (VAL:LON), 3.7
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
THE MONTHLY February 2019
Time Finance plc (TIME:LON), 37.2 | Advanced Oncotherapy Plc (AVO:LON), 1.9 | AJ Bell Plc (AJB:LON), 300 | Allergy Therapeutics plc (AGY:LON), 2.7 | Arbuthnot Banking Group PLC (ARBB:LON), 1,065 | Avacta Group PLC (AVCT:LON), 50.2 | Amala Foods Plc (DISH:LON), 0 | Burford Capital Limited (BUR:LON), 1,143 | City of London Investment Group PLC (CLIG:LON), 326 | DP Poland PLC (DPP:LON), 11.5 | Gateley (Holdings) Plc (GTLY:LON), 123 | Genedrive Plc (GDR:LON), 3.4 | Haydale Graphene Industries Plc (HAYD:LON), 0.5 | Koovs (KOOV:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Oxford BioMedica plc (OXB:LON), 191 | Palace Capital plc (PCA:LON), 226 | R.E.A. Holdings plc (RE:LON), 70.0 | Redx Pharma Plc (REDX:LON), 21.5 | Shield Therapeutics Plc (STX:LON), 2.1 | Surface Transforms PLC (SCE:LON), 9.6 | 600 Group PLC (SIXH:LON), 2.6 | Tissue Regenix Group plc (TRX:LON), 68.5 | Titon Holdings Plc (TON:LON), 80.0 | Volta Finance Limited (VTA:LON), 512 | Warpaint London PLC (W7L:LON), 420 | ValiRx PLC (VAL:LON), 3.7
- Published:
05 Feb 2019 -
Author:
Hardman & Co Research Team -
Pages:
48
This Investment Research Paper addresses the issue of renewable power generation in the UK and in mainland Europe, which – after the deep-seated financial crisis of 2008/09 and the ensuing recession – now has better prospects of achieving critical mass. It also considers investment perspectives.